Krystal Biotech, Inc. Company Profile
Background
Krystal Biotech, Inc. is a commercial-stage biotechnology company headquartered in Pittsburgh, Pennsylvania. Founded in 2016, the company is dedicated to developing and delivering genetic medicines for patients with severe, life-threatening, or rare diseases that have limited or no approved therapies. Krystal's mission is to bring transformative gene delivery medicines to patients with high unmet medical needs.
Key Strategic Focus
Krystal Biotech's strategic focus centers on the discovery, development, and commercialization of genetic medicines using its proprietary redosable gene therapy platform. The company's core objectives include:
- Developing Redosable Gene Therapies: Utilizing a modified and engineered HSV-1 vector that is replication-defective and non-integrating to deliver therapeutic transgenes to target cells.
- Addressing High Unmet Medical Needs: Focusing on severe, life-threatening, or rare diseases with limited or no approved treatments.
- Expanding Therapeutic Areas: Broadening the scope of genetic therapies to include various conditions beyond the initial focus.
The company primarily targets markets in the United States, aiming to provide innovative treatments for patients with rare and debilitating diseases.
Financials and Funding
As of May 2, 2026, Krystal Biotech's stock (NASDAQ: KRYS) is trading at $266.04, with a market capitalization of approximately $7.94 billion. The company reported revenues of $389.13 million for the trailing twelve months, reflecting a 33.94% increase from the previous year. Net income for the same period was $204.83 million, marking a 129.74% increase.
Krystal Biotech has successfully raised capital through multiple funding rounds, including a significant post-IPO equity round in June 2023, raising $160 million. Notable investors include Redmile Group and Avoro Capital Advisors. The capital raised is intended to support the commercialization of VYJUVEK and the advancement of the company's diverse pipeline of genetic therapies.
Pipeline Development
Krystal Biotech's pipeline includes several promising candidates:
- VYJUVEK (beremagene geperpavec-svdt): The first and only redosable gene therapy approved for the treatment of dystrophic epidermolysis bullosa (DEB).
- KB803: Developed for ocular complications of DEB.
- KB801: Targeting neurotrophic keratitis.
- KB407: In Phase 1 clinical trials for cystic fibrosis.
- KB111: Developed for Hailey-Hailey disease.
- KB707: Aimed at solid tumors, with ongoing Phase 1/2 clinical trials for anti-PD-1 relapsed/refractory cases.
- KB408: In Phase 1 clinical trials for Alpha-1 antitrypsin deficiency.
- KB301: In Phase 2 clinical trials for aesthetic skin conditions, with an open-label study using ophthalmic B-VEC for treating ocular complications of DEB.
Technological Platform and Innovation
Krystal Biotech's proprietary technology platform, known as STAR-D, utilizes a modified and engineered HSV-1 vector that is replication-defective and non-integrating. This platform enables the delivery of therapeutic transgenes to target cells, offering a redosable gene therapy approach. The company operates in-house cGMP facilities, Ancoris and Astra, to produce its gene therapies, ensuring control over manufacturing processes and product quality.
Leadership Team
Krystal Biotech is led by an experienced management team:
- Krish S. Krishnan: Founder, Chairman, President, and Chief Executive Officer.
- Suma M. Krishnan: Founder, President of Research and Development, and Director.
- John Karakkal: Vice President of North American Sales and Marketing.
- Dr. Stephane Paquette, Ph.D.: Senior Vice President of Corporate Development.
- Dr. David Chien, M.D.: Senior Vice President of Clinical Development.
- Christine Wilson: Senior Vice President and Head of U.S. Commercial.
- Trevor Parry, Ph.D.: Senior Vice President of Product Development.
- David Sweet: Director of Clinical Development.
Market Insights and Competitor Profile
The biotechnology industry, particularly in the field of gene therapies for rare diseases, is experiencing significant growth. Advancements in genetic medicine and increasing investment in rare disease treatments contribute to a dynamic and competitive market landscape.
Krystal Biotech operates in a competitive environment with several key players:
- Johnson & Johnson: A global leader in pharmaceuticals and biotechnology, with a diverse portfolio and substantial market presence.
- Merck & Co., Inc.: A major pharmaceutical company involved in various therapeutic areas, including oncology and immunology.
- Pfizer Inc.: A multinational corporation with a broad range of pharmaceutical products and a strong focus on research and development.
- AbbVie Inc.: A biopharmaceutical company specializing in immunology, oncology, and neuroscience.
